| Market Capitalization (Millions $) |
1,166 |
| Shares
Outstanding (Millions) |
47 |
| Employees |
57 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-104 |
| Cash Flow (TTM) (Millions $) |
57 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Dice Therapeutics Inc. is a biotechnology company that focuses on developing new medicines for patients with rare endocrine and metabolic disorders. The company is headquartered in San Francisco, California, and it was founded in 2020 by a team of experienced biotechnology executives.
The main focus of Dice Therapeutics Inc. is to develop next-generation gene therapies and hormone replacement therapies to treat endocrine and metabolic disorders. These therapies aim to provide patients with long-term benefits by correcting genetic defects that cause these disorders.
The company's research and development efforts are focused on three key areas:
Gene Therapy: Dice Therapeutics Inc. is developing gene therapies to address rare genetic diseases that affect hormone production and regulation. The company uses its proprietary technology to deliver genes that can correct or replace malfunctioning genes in patients.
Hormone Replacement Therapy: The company is developing hormone replacement therapies for patients with rare endocrine disorders, including those that affect the pituitary, adrenal, and thyroid glands. The company's hormone therapy aims to provide long-term, stable hormone replacement that can improve quality of life for patients.
Drug Discovery: Dice Therapeutics Inc. is conducting research on new compounds that can be used to treat rare endocrine and metabolic disorders. The company uses state-of-the-art screening technologies to identify potential drug candidates.
The company's management team includes experienced biotechnology executives who have a proven track record of developing successful therapies for rare diseases. The team includes Dr. Douglas E. Williams as CEO, Dr. Alan J. Lewis as Chairman of the Board, and Dr. Vikas Goyal as Chief Medical Officer.
In conclusion, Dice Therapeutics Inc. is a biotechnology company with a clear mission to develop new therapies for patients with rare endocrine and metabolic disorders. The company's focus on gene therapy, hormone replacement therapy, and drug discovery makes it well-positioned to address these challenging diseases. With an experienced management team and a commitment to innovation, Dice Therapeutics Inc. is a promising company in the biotechnology space.
Company Address: 400 East Jamie Court South San Francisco 94080 CA
Company Phone Number: 566-1420 Stock Exchange / Ticker: NASDAQ DICE
|
1.64%